

Supplementary Data

Ester prodrugs of levofloxacin to prevent chelate formation in presence of aluminium ion

Yorinobu Maeda^{1*}, Yuka Takahashi¹, Yuki Naika¹, Takato Maeda¹, Yuki Otsuka¹, Yumi Saeki¹, Saki Otani¹, Kunihiro Kohama², Yuhzo Hieda¹, Takeshi Goromaru¹, Seiji Eto¹, Teruo Murakami³

¹ Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.

² Department of Pharmacy, Chugoku-Rosai Hospital, Hiroshima, Japan.

³ Faculty of Pharmaceutical Sciences, Hiroshima International University, Hiroshima, Japan.


*Corresponding author: Yorinobu Maeda. Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Gakuencho 1 Sanzou, Fukuyama, Hiroshima 729-0292, Japan.

TEL: +81-84-936-2111


FAX: +81-84-936-2024

y.maeda@fukuyama-u.ac.jp

(A)



(B)



(C)






Figure S1. Spectrum of ^1H -NMR (A), ^{13}C -NMR (B) and Mass (C) of LVFX-CLX

(A)



(B)



(C)






Figure S2. Spectrum of ^1H -NMR (A), ^{13}C -NMR (B) and Mass (C) of LVFX-EHE

(A)



(B)



(C)






Figure S3. Spectrum of ^1H -NMR (A), ^{13}C -NMR (B) and Mass (C) of LVFX-MDX

(A)



(B)



(C)




Figure S4. Spectrum of ^1H -NMR (A), ^{13}C -NMR (B) and Mass (C) of LVFX-PVM